IL1B and preeclampsia: Growing evidence supports the clinical benefits and anti-inflammatory effects of drugs targeting the NLRP3 inflammasome and IL-1β pathway in several diseases (61), but whether they are pregnancy-safe and effective in preeclampsia needs to be determined.